Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canntab O.D. tablet
- Development stage
- Phase 3
- Lead developer
- Canntab Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Buccal, Sublingual
01
Overview
Canntab O.D. tablet (also known as Canntab ODT) is an orally dissolving sublingual cannabinoid tablet developed by Canntab Therapeutics. The formulation contains phytocannabinoids, specifically cannabidiol (CBD) and/or tetrahydrocannabinol (THC), and is designed to dissolve rapidly under the tongue or in the buccal cavity. This route of administration allows the active ingredients to diffuse directly into the bloodstream through sublingual tissue, bypassing first-pass metabolism and achieving a rapid onset of action (typically within 5 to 30 minutes). Canntab utilizes proprietary nano-emulsification technology to enhance the bioavailability of the cannabinoids. The O.D. tablet is intended for conditions requiring fast-acting relief, such as nausea, vomiting, pain, anxiety, and muscle spasms.
- Brand names
- Relief PLUS
- Other names
- Canntab ODTCanntab ODT tabletCanntab Oral Dissolvable TabletOral Dissolving tabletOrally dissolving sublingual cannabinoid tablet
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Canntab O.D. tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canntab O.D. tablet.